Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of uterine cancer called endometrioid endometrial carcinoma, confirmed by laboratory testing of tissue.
• People whose cancer has spread or come back and cannot be treated with surgery or radiation with the goal of a cure.
• People who have received at least 1 but no more than 4 previous systemic treatments (such as chemotherapy), including both a platinum-based chemotherapy and an immunotherapy checkpoint inhibitor at some point (either together or separately). People who could not receive a checkpoint inhibitor for medical reasons should consult with the trial team directly.
• People whose cancer has a specific gene change in a pathway called PI3K/AKT/mTOR (confirm with trial site for testing details).
• People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines.
• People who are considered fairly well-functioning physically, based on a standard medical rating scale (a score of 0 or 1 out of 5, meaning fully active or able to carry out light activity).
• Women who are not pregnant and not breastfeeding, and who are either past menopause, have had a surgical procedure that prevents pregnancy, or agree to use effective contraception.

Who may not be able to join:

• People who have cancer that has spread to the brain or spinal cord, unless that cancer has already been treated locally and they have been off steroid medications for that condition for at least 4 weeks before the trial begins.
• People who have had another active cancer in the past 24 months, with some exceptions such as certain skin cancers, fully treated non-invasive cancers (such as of the breast, cervix, or bladder), or cancers that were completely removed by surgery.
• People who have a stomach feeding tube, difficulty absorbing food or medication through the gut, certain types of bowel surgery, a bowel blockage, or any other condition that could affect how the body absorbs the study medication.
• People who have significant or uncontrolled bleeding from the lungs or tumour, as assessed by the treating doctor.
• People who have significant heart or cardiovascular problems.
• People who have an active infection that requires systemic antibiotic, antiviral, or antifungal treatment.
• People who are currently taking part in another clinical trial involving a treatment.
• People who have received radiation therapy within 21 days before starting the study treatment.
• People who are taking certain medications that strongly affect how the body processes other drugs (specifically strong CYP3A4 inhibitors or inducers within 7 days before the first dose, or strong CYP1A2 inhibitors or inducers — confirm specific medications with the trial site).
• People who need to regularly take proton pump inhibitors (PPIs), antacids, or other medications that reduce stomach acid (such as H2 blockers).
• People whose heart electrical activity shows a specific abnormality on an ECG (a QTc interval of more than 480 ms).
• People with poorly controlled blood sugar or high triglyceride (blood fat) levels, or who are currently receiving insulin treatment (confirm specific thresholds with trial site).

Important: Always verify eligibility with the trial site directly before applying.